Predictive Role of KLK10 and Other Neuroinflammatory Molecules on Clinical Outcomes of AIS (NCT06549972) | Clinical Trial Compass
CompletedNot Applicable
Predictive Role of KLK10 and Other Neuroinflammatory Molecules on Clinical Outcomes of AIS
China273 participantsStarted 2024-08-12
Plain-language summary
This study aims to investigate the dynamic changes and differential expression characteristics of neuroinflammatory molecules such as kallikrein-related peptidase 10 (KLK10), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), and glial fibrillary acidic protein (GFAP) in the plasma of patients with first-ever anterior circulation acute ischemic stroke (AIS). It will analyze the correlation between these molecules and the severity of neurological deficits, infarct volume, brain edema, hemorrhagic transformation, progressive stroke, and clinical outcomes at three months. The goal is to assess the predictive value of these molecules for AIS prognosis, guiding early treatment and new molecular targets for prevention and treatment.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
for AIS patients:
* Selection of 182 patients with first-ever acute ischemic stroke (AIS) who are hospitalized at our hospital, aged ≥18 years, with no restriction on gender;
* Patients must be admitted within 24 hours of the onset of AIS;
* Diagnosis must be confirmed by cranial magnetic resonance imaging (MRI) or computed tomography (CT);
* All enrolled patients must provide written informed consent.
for healthy controls:
* Age and gender-matched;
* No organic diseases;
* Written informed consent must be signed
Exclusion Criteria:
* Intracranial hemorrhage;
* Pregnancy;
* Stroke with unknown onset time;
* Malignant tumors;
* Hematologic disorders;
* Severe liver or kidney dysfunction;
* Recent myocardial infarction (less than 3 months);
* Ongoing anti-inflammatory drug treatment.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
the Modified Rankin Scale (mRS) score
Timeframe: Record the Modified Rankin Scale (mRS) score at 3 months after stroke onset